as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹504.85
Change
+1.25 (0.25%)
Open
₹504.0
Prev. Close
₹503.6
Day High
₹513.0
Day Low
₹503.05
Volume Analysis
Traded
155,190
Delivered
79,439
Delivery %
51.19%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (28.4%)
- •Strong operating margin (32.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (3)
- •Strong 3-year EPS growth (36.1%)
- •Strong 3-year revenue growth (16.3%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹520.84 | ₹516.92 | ₹510.89 | ₹506.97 | ₹500.94 | ₹497.02 | ₹490.99 |
| Fibonacci | ₹516.92 | ₹513.12 | ₹510.77 | ₹506.97 | ₹503.17 | ₹500.82 | ₹497.02 |
| Camarilla | ₹507.59 | ₹506.67 | ₹505.76 | ₹506.97 | ₹503.94 | ₹503.03 | ₹502.11 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+13.02%
1 Week
+3.45%
1 Month
+10.66%
3 Months
-10.73%
6 Months
+8.37%
1 Year
-66.9%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹89.54
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
22.97%
Net margin 15.38% × asset turnover 1.14x × equity multiplier 1.31x
Company Overview
Sector
Healthcare
Market Cap
₹7,940 Cr
P/E (TTM)
45.3
ROE
28.4%
Book Value
₹34.8
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Thyrocare Tech Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Valuation (7/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (28.4%); strong operating margin (32.0%); promoter holding is falling. Strong 3-year EPS growth (36.1%).
TopFund Score — Fundamentals Quality
66/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has been maintaining a healthy dividend payout of 131%
- −Stock is trading at 14.3 times its book value
- −Promoter holding has decreased over last quarter: -9.90%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Chief Scientific Officer Dr. Preet Kaur resigns; last working day November 6, 2026.
Please find attached the Earnings Call Transcript held on October 29, 2026
Thyrocare signed SPA on Oct 30, 2026 to sell 100% of Nueclear Healthcare for about Rs.141.4 crore.
Please find attached herewith Newspaper Publication of Unaudited Financial Results for the quarter and half year ended on September 30, 2026
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 148 | 135 | 154 | 157 | 177 | 166 | 187 | 193 | 217 | 196 | 224 | 240 | 271 |
| Expenses + | 110 | 103 | 121 | 115 | 129 | 124 | 130 | 135 | 145 | 138 | 149 | 163 | 182 |
| Operating Profit | 38 | 32 | 34 | 42 | 48 | 42 | 57 | 58 | 71 | 58 | 75 | 77 | 89 |
| OPM % | 25.0% | 23.0% | 22.0% | 27.0% | 27.0% | 25.0% | 30.0% | 30.0% | 33.0% | 30.0% | 34.0% | 32.0% | 33.0% |
| Other Income + | 3 | 3 | 3 | 4 | 3 | 4 | 5 | 5 | 3 | -1 | 5 | 5 | -41 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 2 |
| Depreciation | 11 | 13 | 13 | 11 | 13 | 17 | 14 | 11 | 12 | 22 | 14 | 12 | 14 |
| Profit before tax | 28 | 20 | 23 | 34 | 37 | 28 | 47 | 50 | 63 | 35 | 64 | 68 | 34 |
| Tax % | 28.0% | 26.0% | 25.0% | 29.0% | 28.0% | 32.0% | 54.0% | 24.0% | 24.0% | 21.0% | 24.0% | 25.0% | 55.0% |
| Net Profit + | 20 | 15 | 17 | 24 | 26 | 19 | 22 | 38 | 48 | 28 | 49 | 51 | 15 |
| EPS in Rs | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 3 | 2 | 3 | 3 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 10 | 5 | 14 | 16 | 20 | 23 | 21 | 23 | 22 | 18 | 20 | 24 | 25 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 183 | 241 | 304 | 356 | 403 | 434 | 495 | 589 | 527 | 572 | 687 | 829 | 930 |
| Expenses + | 110 | 147 | 189 | 212 | 249 | 261 | 323 | 353 | 403 | 432 | 498 | 566 | 631 |
| Operating Profit | 73 | 94 | 115 | 145 | 154 | 174 | 171 | 236 | 123 | 140 | 190 | 263 | 299 |
| OPM % | 40.0% | 39.0% | 38.0% | 41.0% | 38.0% | 40.0% | 35.0% | 40.0% | 23.0% | 24.0% | 28.0% | 32.0% | 32.0% |
| Other Income + | 8 | 7 | -15 | 21 | 11 | 1 | 12 | 29 | 9 | 9 | 15 | 12 | -32 |
| Interest | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 3 | 5 | 6 | 4 | 4 | 4 |
| Depreciation | 13 | 18 | 18 | 20 | 26 | 32 | 30 | 34 | 39 | 47 | 55 | 59 | 62 |
| Profit before tax | 68 | 82 | 82 | 145 | 138 | 140 | 152 | 228 | 89 | 96 | 145 | 213 | 202 |
| Tax % | 35.0% | 37.0% | 48.0% | 36.0% | 38.0% | 37.0% | 26.0% | 23.0% | 27.0% | 28.0% | 38.0% | 24.0% | — |
| Net Profit + | 44 | 52 | 43 | 93 | 85 | 88 | 113 | 176 | 64 | 69 | 91 | 163 | 143 |
| EPS in Rs | 3 | 3 | 3 | 6 | 5 | 6 | 7 | 11 | 4 | 4 | 6 | 10 | 9 |
| Dividend Payout % | 171.0% | 104.0% | 125.0% | 58.0% | 124.0% | 30.0% | 117.0% | 45.0% | 148.0% | 135.0% | 122.0% | 137.0% | — |
| Sales growth | — | 32 | 26 | 17 | 13 | 8 | 14 | 19 | -11 | 9 | 20 | 21 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 226 | 312 | 354 | 390 | 382 | 314 | 374 | 474 | 481 | 474 | 494 | 426 | 394 |
| Borrowings + | 0 | 0 | 0 | 0 | 2 | 12 | 8 | 21 | 23 | 42 | 25 | 51 | 57 |
| Other Liabilities + | 53 | 44 | 30 | 36 | 37 | 90 | 106 | 60 | 74 | 75 | 121 | 111 | 115 |
| Total Liabilities | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 747 | 725 |
| Fixed Assets + | 196 | 259 | 259 | 299 | 294 | 269 | 253 | 285 | 294 | 306 | 297 | 317 | 289 |
| CWIP | 6 | 1 | 17 | 0 | 1 | 5 | 8 | 3 | 2 | 3 | 14 | 3 | 1 |
| Investments | 86 | 93 | 104 | 120 | 95 | 90 | 126 | 146 | 144 | 162 | 162 | 177 | 168 |
| Other Assets + | 42 | 56 | 58 | 60 | 84 | 105 | 154 | 173 | 192 | 173 | 220 | 250 | 267 |
| Total Assets | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 747 | 725 |
| Equity Capital | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 159 | 159 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 34 | 68 | 90 | 107 | 100 | 168 | 115 | 113 | 129 | 168 | 191 | 213 |
| Cash from Investing Activity + | -18 | -18 | -42 | -43 | -12 | 1 | -49 | -24 | -39 | -91 | -53 | -23 |
| Cash from Financing Activity + | -23 | -45 | -49 | -64 | -94 | -165 | -62 | -89 | -86 | -85 | -130 | -170 |
| Net Cash Flow | -6 | 5 | 0 | 0 | -5 | 4 | 4 | 0 | 4 | -8 | 8 | 21 |
| Free Cash Flow | 25 | 53 | 53 | 63 | 61 | 158 | 93 | 99 | 88 | 107 | 146 | 198 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 79 | 106 | 113 | 108 | 104 | 122 | 92 | 72 | 128 | 141 | 123 | 104 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 11.64% | 11.11% | 11.49% | 12.15% | 11.49% | 11.57% | 11.18% | 10.61% | 13.61% | 12.71% | 12.71% | 13.69% |
| Promoters | 71.11% | 71.11% | 71.11% | 71.11% | 71.06% | 71.06% | 71.06% | 71.06% | 60.93% | 60.92% | 60.92% | 51.02% |
| FII | 3.35% | 2.9% | 2.49% | 1.93% | 2.77% | 2.41% | 3.23% | 4.85% | 4.96% | 5.37% | 5.43% | 9.37% |
| DII | 13.89% | 14.88% | 14.89% | 14.79% | 14.68% | 14.97% | 14.54% | 13.47% | 20.52% | 21.0% | 20.92% | 25.92% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Thyrocare Tech Ltd (this stock) | 7,940 | 45.3 | 14.31 | 28.4% |
| Suven Life Sciences Ltd | 7,850 | — | 17.38 | -81.5% |
| Sanofi India Limited | 7,603 | 17.2 | 8.83 | 47.1% |
| Healthcare Glob. Ent. Ltd | 8,562 | 216.0 | 6.36 | 2.54% |
| Kovai Medical Center & Ho | 7,108 | 123.0 | 24.58 | 22.2% |
| Bliss Gvs Pharma Ltd | 7,075 | 43.5 | 5.5 | 11.8% |
| Sun Pharma Adv.res.co.ltd | 6,680 | 4.05 | 4.64 | 279.0% |
Which Mutual Funds Hold Thyrocare Tech Ltd?
Frequently Asked Questions about Thyrocare Tech Ltd
Thyrocare Tech Ltd (THYROCARE) closed at ₹504.85 on NSE on 19 November 2026, up 1.25 (0.25%) from the previous close.
Thyrocare Tech Ltd trades on the NSE (National Stock Exchange of India) under the symbol THYROCARE.
Thyrocare Tech Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 45.3.
Thyrocare Tech Ltd has a dividend yield of 1.87%.
Thyrocare Tech Ltd's 52-week high is ₹662.0 and its 52-week low is ₹343.0.
Thyrocare Tech Ltd has a market capitalisation of ₹7,940 crore.
Thyrocare Tech Ltd has a TopFund Quality Score of 66/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Thyrocare Tech Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.